Literature DB >> 15062764

The ADVIA Centaur immunoassay system--designed for infectious disease testing.

David Okrongly1.   

Abstract

The ability to automate immunodiagnostics testing is critical for the efficiency of clinical laboratories. For automation of Infectious Disease testing, special design considerations must be made to ensure the integrity of the testing result while at the same time delivering productivity. The ADVIA Centaur was designed with the intent of performing a complete Infectious Disease panel including HBV, HCV, and HIV markers. Features such as disposable sample tips, sample and reagent delivery verification, and clog and clog detection have been incorporated in the design for assay robustness. Productivity features deliver best in class throughput performance for the Infectious Disease assays. Moreover, the underlying technology incorporating flexible assay protocols, universal solid phases and proprietary acridinium ester technology contribute to the assay design flexibility and analytical performance of the ADVIA Centaur immunoassay system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15062764     DOI: 10.1016/j.jcv.2004.02.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  3 in total

1.  Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Barbara Francis; Nicholas Laven; Joan Marler; David Dickeson; Tony Panayotou; Kim Wilson; Robyn Wootten; Elizabeth M Dax
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

2.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

3.  Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors.

Authors:  Sung-Hsi Huang; Chung-Hao Huang; Ning-Chi Wang; Tun-Chieh Chen; Yuan-Ti Lee; Shih-Ping Lin; Te-Yu Lin; Chi-Ying Lin; Yu-Lin Lee; Chen-Hsiang Lee; Cheng-Pin Chen; Kuan-Yin Lin; Guan-Jhou Chen; Chun-Eng Liu; Shu-Hsing Cheng; Po-Liang Lu; Chia-Jui Yang; Chien-Ching Hung
Journal:  Hepatology       Date:  2019-02-14       Impact factor: 17.425

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.